Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Nodoka Umezaki"'
Autor:
Terufumi Yoshida, Tadayoshi Okumura, Yoshiyuki Matsuo, Tetsuya Okuyama, Taku Michiura, Masaki Kaibori, Nodoka Umezaki, Hidemasa Bono, Kiichi Hirota, Mitsugu Sekimoto
Publikováno v:
Nitric Oxide. 124:1-14
Roxadustat and other hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) have recently been approved for the treatment of chronic renal anemia. In macrophages and monocytes, the activation of HIF-1 by pro-inflammatory cytokines induces
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f27e2eaef5e85c7b2971d207e4589511
https://doi.org/10.1016/j.niox.2022.04.002
https://doi.org/10.1016/j.niox.2022.04.002
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 81:412-416
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40855c743a2a2fbb1a15208423382700
https://doi.org/10.3919/jjsa.81.412
https://doi.org/10.3919/jjsa.81.412
Autor:
Mami, Miyata, Nao, Yoshida, Mariko, Ishizuka, Nodoka, Umezaki, Katsuhiro, Yoshikawa, Noriko, Sueoka, Daigo, Yamamoto, Mitsugu, Sekimoto
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 47(13)
A 46-year-old woman with metastatic breast cancer developed dyspnea that progressed relatively rapidly during chemotherapy. Chest-abdominal CT revealed wedge-shaped infiltration shadow, and cardiac catheterization revealed elevated pulmonary artery p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c5be98ddcc9c07ee6678fc4d1e2a0a5d
https://pubmed.ncbi.nlm.nih.gov/33468775
https://pubmed.ncbi.nlm.nih.gov/33468775
Autor:
Nodoka, Umezaki, Yujiro, Ozaki, Noriko, Sueoka, Nao, Yoshida, Daigo, Yamamoto, Mitsugu, Sekimoto
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 47(2)
The demand for breast reconstruction is expected to increase with the currently observed increase in the number of breast cancer patients. Among the 70 patients included in the study, 59 received tissue expanders, 1 received implant, and 10 received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7d2fc9f66c9748dca2cfc62dedc67a31
https://pubmed.ncbi.nlm.nih.gov/32381984
https://pubmed.ncbi.nlm.nih.gov/32381984
Autor:
Mami, Miyata, Nao, Yoshida, Mariko, Ishizuka, Nodoka, Umezaki, Katsuhiro, Yoshikawa, Noriko, Sueoka, Yu, Tsubota, Daigo, Yamamoto, Mitsugu, Sekimoto
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 47(3)
We present the case of an 88-year-old woman who had undergone breast conserving surgery for left breast cancer 8 years ago.She received postoperative radiotherapy(total dose of 60 G/30 Fr)to the residual breast together with endocrine therapy.She und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::75e8966e8e9bbcd051bad92c601959ab
https://pubmed.ncbi.nlm.nih.gov/32381942
https://pubmed.ncbi.nlm.nih.gov/32381942
Autor:
Mariko, Ishizuka, Daigo, Yamamoto, Tetsuji, Shoji, Noriko, Sueoka, Mami, Miyata, Nodoka, Umezaki, Katsuhiro, Yoshikawa, Nao, Yoshida, Hirotsugu, Sekimoto
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 46(13)
Nipple discharge is a common symptom and frequently results from benign tumors. However, there is a 5-30% risk of malignancy. A 65-year-old woman presented at the hospital because of bloody nipple discharge in her right breast. She had noticed an abn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e683278d3b8e9533f0ca6ebb651cbc75
https://pubmed.ncbi.nlm.nih.gov/32156924
https://pubmed.ncbi.nlm.nih.gov/32156924
Autor:
Kanako Kawaguchi, Nayuko Sato, Hiroya Fujioka, Kazuhisa Uchiyama, Risa Terasawa, Junna Matsuda, Nodoka Umezaki, Kosei Kimura, Mitsuhiko Iwamoto, Satoru Tanaka
Publikováno v:
Molecular and Clinical Oncology. 5:385-390
The purpose of this study was to retrospectively analyze the feasibility of outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer. A total of 131 consecutive patients with breast canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9be54769104a09501746cca50e9d55de
https://doi.org/10.3892/mco.2016.992
https://doi.org/10.3892/mco.2016.992
Autor:
Hiyoya Fujioka, Kanako Kawaguchi, Kazuhisa Uchiyama, Yuko Takahashi, Saki Maezawa, Kosei Kimura, Nodoka Umezaki, Tomo Tominaga, Ayana Ikari, Nayuko Sato, Satoru Tanaka, Mitsuhiko Iwamoto, Risa Terasawa, Junna Matsuda
Publikováno v:
Anticancer research. 36(12)
Background: There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1373ec52ae56abe9de467fbdca38ca9b
https://pubmed.ncbi.nlm.nih.gov/27919974
https://pubmed.ncbi.nlm.nih.gov/27919974
Autor:
Risa, Terasawa, Mitsuhiko, Iwamoto, Satoru, Tanaka, Kosei, Kimura, Yuko, Takahashi, Hiroya, Fujioka, Nayuko, Sato, Kanako, Kawaguchi, Ayana, Ikari, Saki, Maezawa, Tomo, Tominaga, Junna, Matsuda, Nodoka, Umezaki, Kazuhisa, Uchiyama
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 43(6)
Squamous cell carcinoma(SCC)of the breast is a rare disease. We encountered a case of SCC of the breast that relapsed in the early postoperative period and rapidly progressed thereafter. A 38-year-old woman visited our hospital presenting with a tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e974c435ef9a7a2221d07fa76b6eeec8
https://pubmed.ncbi.nlm.nih.gov/27306813
https://pubmed.ncbi.nlm.nih.gov/27306813
Autor:
Nayuko Sato, Juuna Matsuda, Kazuhisa Uchiyama, Nodoka Umezaki, Mitsuhiko Iwamoto, Kanako Kawaguchi, Kosei Kimura, Hiroya Fujioka, Risa Terasawa, Satoru Tanaka
Publikováno v:
Journal of Clinical Oncology. 34:e12035-e12035
e12035Background: Eribulin mesylate demonstrated to significant improvement in overall survival (OS) in patients with heavily pretreated, locally recurrent or metastatic breast cancer when compared to treatment of physician’s choice. On the other h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c79be4ceabf204f7071143134d8e848e
https://doi.org/10.1200/jco.2016.34.15_suppl.e12035
https://doi.org/10.1200/jco.2016.34.15_suppl.e12035